Hidradenitis Suppurativa Therapeutics Pipeline Review, H1 2015 offers “Hidradenitis Suppurativa – Pipeline Review, H1 2015”global research report on its store.

This report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available at .

Scope of The Report:

  • The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hidradenitis Suppurativa and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hidradenitis Suppurativa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hidradenitis Suppurativa pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy This Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a copy of this report at .

Table of Content for “Hidradenitis Suppurativa – Pipeline Review, H1 2015” research report includes:

Hidradenitis Suppurativa Overview 6

Therapeutics Development 7

Pipeline Products for Hidradenitis Suppurativa - Overview 7

Pipeline Products for Hidradenitis Suppurativa - Comparative Analysis 8

Hidradenitis Suppurativa - Therapeutics under Development by Companies 9

Hidradenitis Suppurativa - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Hidradenitis Suppurativa - Products under Development by Companies 13

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development 14

AbbVie Inc. 14

Delenex Therapeutics AG 15

Johnson & Johnson 16

Hidradenitis Suppurativa - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

adalimumab - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

adalimumab biosimilar - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

DLX-105 - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

DLX-2751 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ustekinumab - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Hidradenitis Suppurativa - Recent Pipeline Updates 35

Hidradenitis Suppurativa - Dormant Projects 44

Hidradenitis Suppurativa - Discontinued Products 45

Hidradenitis Suppurativa - Product Development Milestones 46

Featured News & Press Releases 46

Oct 13, 2014: AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress 46

Sep 11, 2014: AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease 47

Sep 11, 2014: Delenex Announces New Clinical Data 48

Oct 03, 2013: AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa 49

Mar 15, 2012: Abbott Announces Patient Enrollment In Two Phase III Studies Of HUMIRA For Moderate To Severe Hidradenitis Suppurativa 50

Priced at US $2000 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. ( ).